AKRIKHIN is one of the leading Russian pharmaceutical companies producing high-quality medicines of therapeutic groups most demanded in Russia: dermatology, cardiology, neurology, gynaecology, pulmonology, endocrinology, and others. The company’s product portfolio includes about 200 pharmaceuticals, more than 45% of them belong to the list of vital and essential drugs.  

All AKRIKHIN products are made in full compliance with the international GMP standards. It is worth noting that throughout its activities, the company has built its own quality system, and in 1999, it was the first in Russia to get a GMP certificate from a German government authorised body for the industrial production of cardiovascular drugs. In 2015, AKRIKHIN was granted a GMP certificate by the Ministry of Industry and Trade of Russia and successfully confirmed it in 2018. 

The company’s production facilities undergo regular Russian and international quality audits; by now, more than 60 of them have been conducted. AKRIKHIN has its own Quality Control Centre, which on average tests about 1,800 batches of raw materials and 3,000 batches of packaging materials a year. Also, the Centre annually outputs about 3,700 batches of finished products with quality certificates.  

The company is a long-standing partner of the All-Russian GMP Conference presenting its best practices at sessions and workshops of the forum. This year, AKRIKHIN representatives will also participate in the Conference events. With the support of the company, on 22 September, a panel discussion “Current Development of Pharmaceutical Market: Time and Place for System Expertise” will take place.  

The event will be attended by representatives of the Ministry of Industry and Trade of Russia, Federal State Institution State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of Russia, National Centre for Reference Standards, industry communities and associations, as well as pharmaceutical companies.  

The participants will discuss such issues as a system for domestic pharmaceutical inventions and full-cycle production facilities, technology transfer and production upscaling, introduction of a system of national reference standards in Russia, and other important topics.